Avita Medical (ASX:AVH) lowered its commercial revenue guidance for the fourth quarter of 2024 to AU$18.4 million from the previous AU$22.3 million to AU$24.3 million, according to a Wednesday filing with the Australian bourse.
The downgrade was due to a "more pronounced" slowdown in purchasing activity during the reported period, with deferred purchases expected to pick up in the first quarter of the year, the filing said.
In addition, the regenerative medicine company decreased its 2024 commercial revenue forecast to AU$64.3 million from the previous AU$68 million to AU$70 million, per the filing.
Avita Medical anticipates commercial revenue in the range of AU$100 million to AU$106 million in 2025 as it expects to achieve profitability by the fourth quarter instead of the third quarter, the filing added.
Company shares slumped almost 20% in recent Wednesday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。